Ono Pharmaceutical Co., Ltd. (OPHLY)
| Previous Close | 4.9300 |
| Open | 4.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.8783 - 5.0200 |
| 52 Week Range | 4.7100 - 6.8000 |
| Volume | |
| Avg. Volume | 119,527 |
| Market Cap | 7.075B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 8.86 |
| EPS (TTM) | 0.5600 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | 0.18 (3.56%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | N/A |
PR NewswireONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow
- Reuters
Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
- Reuters
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
